Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Delta-Fly Pharma, Inc.
No Price
Closing Price XTKS 28.04.2026:
198,00 JPY
28.04.2026 06:30
Current Prices from Delta-Fly Pharma, Inc.
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
Tokyo
4598.T
JPY
28.04.2026 06:30
198,00 JPY
1,00 JPY
+0,51 %
Share Float & Liquidity
Free Float83,98 %
Shares Float10,21 M
Shares Outstanding12,16 M
Company Profile for Delta-Fly Pharma, Inc. Share
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
